FDA addresses reviewer goals for modular product submissions
This article was originally published in Clinica
The FDA has drafted two proposed performance goals to measure progress on review times for modular premarket approval applications. These novel submissions were created in 1998 so that companies could submit preclinical data and manufacturing information for review in sections or modules while still collecting, compiling and analysing their clinical data. MDFUMA codified the new submission but let the agency put off the development of performance goals until later on.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.